Latest Publications
Most recently published records currently stored in SQLite.
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
ClinicalTrials.gov · 2026-07-01
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia
Revista CienciaUANL · 2026-06-30
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión
Multidisciplinary Collaborative Journal · 2026-06-30
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Journal of Drug Issues · 2026-06-30
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.gov · 2026-06-30
Psilocybin shows mixed results for patients with treatment-resistant depression
The Brown University Psychopharmacology Update · 2026-06-30
Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation
The Brown University Psychopharmacology Update · 2026-06-30
Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports · 2026-06-30
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
Palliative medicine · 2026-06-30
Qualitative analysis of synthetic opioids, synthetic hallucinogens and LSD in urine using LC-MS/MS
Synthetic opioids and synthetic hallucinogens continue to expand in the illicit drugs market where they are designed and synthesized to avoid detection in routine drug tests. It is therefore crucial for laboratories to develop analytical methods for the detection of these drugs in urine. A method for the simultaneous analysis of synthetic opioids (including ...
Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study
Abstract Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5-HT2A R) agonist psilocybin. However, no studies have investigated whether 5-HT2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy...
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse...
Personal
Personal James Davis (bio) Give me a faggot, fashion mags evenly fannedacross his coffee table, who serves drinksin snifters, tumblers, flutes, and says behind, not to euphemize ass, but to signal his nearing,e.g. on a bike. Give me a man like an otter,svelte swimmer with claws to tear flesh from pink varicellate shells, fur matted with saltwater.I want a mo...
Sprang
Sprang Arthur Sze (bio) 1 winter stars You will never forget corpses wrapped in flames-at dusk, you watched a congregation of crows gather in the orchard and sway on branches;in the dawn light, a rabbit moves and stops, moves and stops along the grass; and asyou pull a newspaper out of a box, glance at the headlines, you feel the dew on grassas the gleam of ...
THE POTENTIAL THERAPEUTIC VALUE OF PSILOCYBIN: In Relation to Depression
Depression is one of the most disabling and prevalent mental disorders, which causes excessive feelings of sadness and despair. Unfortunately, there are a substantial number of patients that do not respond well to conventional interventions and new approaches are therefore needed. Recent studies have revealed that psilocybin can effectively reduce symptoms o...
Serotonergic Psychoactive Compounds as a Treatment for Addiction, Anxiety, and Depression: Their Efficacy and Legality
The United States is a leader in world-wide medical innovation, but currently we face an epidemic of mental health disorders. Serotonergic psychoactive compounds such as psilocybin, mescaline, DMT, and LSD are currently being studied as potential treatments to be used in psychiatric medicine. Currently these substances are prohibited and designated to the st...
The Psychedelic Altered State of Consciousness: An Assessment of the Current Status of Psychedelic Research
Classic psychedelic substances, such as lysergic acid diethylamide and the active compound in magic mushrooms, psilocybin, are being studied again in a renaissance of psychedelic research. Psychedelic substances have profound effects on perception, emotion, and cognition, as well as the capacity to induce mystical-type experiences and ego-dissolution. Recent...
Substance & Seduction: Ingested Commodities in Early Modern Mesoamerica ed. by Stacey Schwartzkopf and Kathyrn E. Sampeck
Reviewed by: Substance & Seduction: Ingested Commodities in Early Modern Mesoamerica ed. by Stacey Schwartzkopf and Kathyrn E. Sampeck Kent Mathewson Stacey Schwartzkopf and Kathyrn E. Sampeck, eds. Substance & Seduction: Ingested Commodities in Early Modern Mesoamerica. Austin: University of Texas Press, 2017. vxii and 220 pp. Figures., notes, bibliography,...
Use of MDMA & Psilocybin in the Treatment of PTSD
For years, the promise of psychedelics in therapeutic settings has been deterred by their general illegality. However, present day research shows promise in treating varying mental disorders. Amongst these disorders is Post Traumatic Stress Disorder (PTSD). According to the organization, PTSD United, PTSD presently effects about eight percent of Americans. M...
Peak experiences in a consciousness landscape - report on the science of consciousness conference in Interlaken, Switzerland, 2019
Introduction \nThe Science of Consciousness (TSC) 2019 was the 26th international interdisciplinary conference in the series that started in Tucson in 1994. This one was held in late June in the beautiful Swiss town of Interlaken, between two lakes and surrounded by high alps. The local organizer was Harald Atmanspacher from Collegium Helveticum in Zuri...
Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs
Background: Contemporary research indicates that the legal classifications of cannabis (Schedule 2, Class B), 3,4-methylenedioxymethamphetamine (MDMA) (Schedule 1, Class A) and psilocybin (Schedule 1, Class A) in the United Kingdom are not entirely based on considerations of harm and therapeutic utility. The legal classifications of the substances discussed ...
Effects of psilocybin on functional connectivity measured with fNIRS: Insights from a single-subject pilot study
The serotonergic hallucinogen psilocybin has characteristic effects on human brain activity and subjective experience. Previous functional magnetic resonance imaging (fMRI) studies showed alternations of functional connectivity (FC) under the influence of psilocybin in humans. No study, as yet, investigated psilocybin-induced changes in brain hemodynamics an...
Multi-targeting cytotoxic drug leads from mushrooms
Due to genetic and epigenetic mechanisms, cancer have become a resistant disease and there is a need for new molecules having multiple targeting action that promotes apoptosis. Phyto-molecules having multiple targeting anticancer activity are in high demand and there is less documentation or information available on these metabolites. It is evident that mush...
2018: A watershed year for psychedelic science
While interest in the study of psychedelic drugs has increased over much of the last decade, in this article, we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in 2018 significantly elevated the status and long-term outlook of psychedelic science, particularly in the Uni...